Inovio Extends Series A Warrants, Enhancing Capital Flexibility

The latest announcement is out from Inovio Pharmaceuticals ( (INO) ).

On January 27, 2026, Inovio Pharmaceuticals amended the terms of its outstanding Series A warrants, originally issued in a July 2025 underwritten public offering, to extend their expiration from January 28, 2026 to 5:00 p.m. New York City time on March 31, 2026. The Series A warrants, which remain unchanged in all other respects, are exercisable for up to 13,564,268 shares of common stock or equivalent pre-funded warrants at an exercise price of $1.75 per share (or $1.749 per pre-funded warrant), a move that gives investors more time to exercise their warrants and potentially provides Inovio with additional access to equity capital tied to its progress on INO-3107 following the FDA’s acceptance of its Biologic License Application.

The most recent analyst rating on (INO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.

Spark’s Take on INO Stock

According to Spark, TipRanks’ AI Analyst, INO is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, large losses, heavy cash burn and negative equity risk) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include constructive clinical/regulatory progress for INO-3107 (BLA submitted and accepted) and improved cost control, but near-term funding/cash runway constraints remain a key risk.

To see Spark’s full report on INO stock, click here.

More about Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA-based immunotherapies and vaccines, including candidates such as INO-3107, targeting various infectious diseases and conditions requiring biologic treatments in the U.S. market.

Average Trading Volume: 1,556,595

Technical Sentiment Signal: Strong Sell

Current Market Cap: $103.7M

See more insights into INO stock on TipRanks’ Stock Analysis page.